Related Experiment Videos
Medical management of hypercalcaemia
1Department of Medicine and Therapeutics, Aberdeen University Medical School, Foresterhill Hospital.
Insights
Hypercalcaemia management involves treating the underlying cause or using medications to lower calcium levels. Intravenous bisphosphonates are the primary treatment, with other drugs used for severe or rapid-onset cases.
Area of Science:
- Endocrinology
- Nephrology
- Oncology
Background:
- Hypercalcaemia is a prevalent condition requiring prompt treatment to prevent organ damage and mortality.
- While addressing the root cause is ideal, pharmacological interventions are crucial for symptom control and managing untreatable conditions.
Purpose of the Study:
- To outline current medical therapies for hypercalcaemia.
- To detail the efficacy and application of various antihypercalcaemic agents.
Main Methods:
- Review of established medical treatments for hypercalcaemia.
- Analysis of pharmacological agents targeting bone resorption and renal calcium excretion.
Main Results:
- Intravenous bisphosphonates are the first-line therapy for initial hypercalcaemia management, offering sustained bone resorption inhibition.
- Calcitonin provides rapid but short-term effects, useful in severe cases, often combined with bisphosphonates.
- Intravenous phosphate and corticosteroids have limited or specific roles in hypercalcaemia treatment.
Conclusions:
- Bisphosphonates are central to hypercalcaemia management due to their sustained efficacy.
- Therapeutic choices depend on the severity and desired onset of action, with combination therapy sometimes indicated.
Abstract:
1. Hypercalcaemia is a common disorder, which frequently requires specific treatment either to control symptoms, or to prevent the development of irreversible organ damage or death. Although the best and most effective way of controlling hypercalcaemia in the long-term is to treat the underlying cause, medical antihypercalcaemic therapy is often required in clinical practice, either as a holding measure, or because the primary disease cannot itself be treated. 2. The mainstays of medical antihypercalcaemic therapy are firstly, to promote calcium excretion by the kidney by restoring extracellular volume with intravenous saline and secondly, to administer pharmacological agents which inhibit bone resorption. Measures which seek to reduce intestinal calcium absorption are seldom effective. 3. Intravenous bisphosphonates are the treatment of first choice for the initial management of hypercalcaemia, followed by continued oral, or repeated intravenous bisphosphonates to prevent relapse. These drugs have a relatively slow onset of action (1-3 days) but have potent and sustained inhibitory effects on bone resorption, resulting in a long duration of action (12-30 days). 4. Of the other agents available, calcitonin has an important place in the management of severe hypercalcaemia where a rapid effect is desirable; calcitonin is best used in conjunction with a bisphosphonate however, because of its short duration of action. Intravenous phosphate also has a place in the emergency management of severe hypercalcaemia, but is probably best reserved for patients in whom other less toxic therapies have failed. Corticosteroids are generally ineffective except in certain specific instances and are best avoided in the routine treatment of undiagnosed hypercalcaemia.